Mark Lievonen Appointed Chair, Rx&D Board of Directors

OTTAWA, November 20, 2013 – Canada’s Research-Based Pharmaceutical Companies (Rx&D) is pleased to announce the appointment of Mark Lievonen, President of Sanofi Pasteur Limited, as Chair of Rx&D’s Board of Directors for 2013-2014. Mr. Lievonen assumed the role during Rx&D’s Annual General meeting held in Montreal on November 20, 2013.

Mr. Lievonen has been an industry leader for over 30 years.  He has served as a member of Rx&D’s Board of Directors, Executive Committee and Chair of several committees.

“I’m proud to play a role in Canada’s healthcare industry.  There is no greater value than preventing disease and improving lives,” said Mark Lievonen.  “I am energized by the work that our industry does, inspired by my passionate colleagues and happy to have the opportunity to represent the Sanofi Group in Canada in my capacity as Chair of Rx&D.”

Mark Lievonen has been President of Sanofi Pasteur Limited since 1999. Under his visionary leadership, Sanofi Pasteur has become a billion dollar enterprise in Canada, with global manufacturing and research & development mandates.  Mr. Lievonen is a Director of Oncolytics Biotech Inc. He also serves on the boards of the Ontario Institute for Cancer Research, the Public Policy Forum, York University, BIOTECanada and the Markham-Stouffville Hospital Foundation.  Mr. Lievonen was awarded the Queen's Jubilee Medallion in 2002 and 2012, the Chevalier de l'Ordre national de Mérite in 2007 and in 2013, he was inducted into the Canadian Healthcare Marketing Hall of Fame.

“Let me be the first to welcome Mark Lievonen. He has been a valued member of Rx&D’s Board of Directors and Executive Committee for several years,” commented Russell Williams, President Rx&D. “We look forward to working together to bring innovation to the forefront.”

About Rx&D

Rx&D is the association of leading research-based pharmaceutical companies dedicated to improving the health of Canadians through the discovery and development of new medicines and vaccines. Our community represents the men and women working for more than 50 member companies which invest more than $1 billion in research and development each year to fuel Canada’s knowledge-based economy, contributing over $3 billion to the Canadian economy.  Guided by our Code of Ethical Practices, our membership is committed to working in partnership with governments, healthcare professionals and stakeholders in a highly ethical manner.

- 30 -

For further information:

Julie Harris
Media Relations
Telephone: 613-236-0455 extension 212
E-mail: jharris@canadapharma.org